NOVACYT news, videos and press releases
For more news please use our advanced search feature.
NOVACYT - More news...
NOVACYT - More news...
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): DHSC Claim Update – Trial Date Listed
- Novacyt S.A. ("Novacyt", the "Company" or the "Group") Full Year 2022 Trading Update
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Non-Executive Director Change
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of genesig® COVID-19 3G PCR Test in the UK Under CTDA Legislation
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Directorate Change
- Novacyt S.A.: Approval of genesig® SARS-CoV-2 Winterplex® 3 Gene Assay Panel in the UK Under CTDA Legislation
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2022 Results
- Launch of Novacyt’s first fully lyophilised PROmate® assays
- Novacyt S.A. (“Novacyt”, the “Company” or the “Group”): Launch of Research-Use-Only Adenovirus F41 Assay
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of exsig™ COVID-19 Direct Test in the UK Under CTDA Legislation
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Trading Update and Progress Against Strategy for H1 2022
- Novacyt S.A.: Launch of Monkeypox Assay
- Novacyt S.A.: CTDA Approval of PROmate® COVID-19 1 Gene and Grant of CE Mark for COVID-19 Lateral Flow Self-Test
- Novacyt S.A. (“Novacyt”, the “Company” or the “Group”): Publication of Annual Report and AGM voting
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Full year 2021 results and update on growth strategy
- Novacyt S.A. ("Novacyt", the "Company" or the "Group") DHSC Dispute Update
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of the First Direct-to-PCR COVID-19 Test in the UK Under CTDA Legislation
- Novacyt S.A. ("Novacyt", the "Company" or the "Group") Strategy and Full Year 2021 Trading Update
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Approval of COVID-19 Test in the UK under CTDA Legislation
- Novacyt S.A. ("Novacyt" or the "Company"): Validation of COVID-19 Tests in the UK under CTDA Legislation
- Novacyt S.A. ("Novacyt", the "Company" or the “Group”): R&D update
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Half Year 2021 Results
- Novacyt S.A.: Proposed Accounting Treatment of Ongoing DHSC Dispute in 2021 Interim Results
- Novacyt S.A.: Half Year Update
- Novacyt S.A.: David Allmond Announced as CEO Following Decision by Graham Mullis to Retire
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Expansion of PathFlow® COVID-19 Lateral Flow Test Portfolio
- Novacyt S.A.: Full Year 2020 Results and Update on Growth Strategy
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Launch of two new PCR COVID-19 assays
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Launch of VersaLab™ Portable
- Novacyt S.A. ("Novacyt", the "Company" or the "Group"): DHSC Dispute Update
